<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7806090</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6166</journal-id>
<journal-id journal-id-type="nlm-ta">Neurosci Biobehav Rev</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurosci Biobehav Rev</journal-id>
<journal-title-group>
<journal-title>Neuroscience and biobehavioral reviews</journal-title>
</journal-title-group>
<issn pub-type="ppub">0149-7634</issn>
<issn pub-type="epub">1873-7528</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">26780584</article-id>
<article-id pub-id-type="pmc">4790729</article-id>
<article-id pub-id-type="doi">10.1016/j.neubiorev.2016.01.001</article-id>
<article-id pub-id-type="manuscript">NIHMS763217</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Therapeutic Potential of Insulin-Like Growth Factor-1 in Central Nervous System Disorders</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Costales</surname>
<given-names>Jesse</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kolevzon</surname>
<given-names>Alexander</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="aff" rid="A2">b</xref>
<xref ref-type="aff" rid="A3">c</xref>
<xref ref-type="aff" rid="A4">d</xref>
<xref ref-type="aff" rid="A5">e</xref>
<xref ref-type="corresp" rid="cor1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY</aff>
<aff id="A2"><label>b</label>Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY</aff>
<aff id="A3"><label>c</label>Seaver Autism Center for Research and Treatment, Icahn School of Medicine at Mount Sinai, New York, NY</aff>
<aff id="A4"><label>d</label>Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY</aff>
<aff id="A5"><label>e</label>Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY</aff>
<author-notes>
<corresp id="cor1"><label>*</label><bold>Corresponding Author</bold>, Alexander Kolevzon, MD, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1230, New York, NY 10029, <email>alexander.kolevzon@mssm.edu</email>, Tel: 212-659-9134, Fax: 212-659-8710</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>7</day>
<month>3</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>1</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>4</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>4</month>
<year>2017</year>
</pub-date>
<volume>63</volume>
<fpage>207</fpage>
<lpage>222</lpage>
<!--elocation-id from pubmed: 10.1016/j.neubiorev.2016.01.001-->
<abstract>
<p id="P1">Central nervous system (CNS) development is a finely tuned process that relies on multiple factors and intricate pathways to ensure proper neuronal differentiation, maturation, and connectivity. Disruption of this process can cause significant impairments in CNS functioning and lead to debilitating disorders that impact motor and language skills, behavior, and cognitive functioning. Recent studies focused on understanding the underlying cellular mechanisms of neurodevelopmental disorders have identified a crucial role for insulin-like growth factor-1 (IGF-1) in normal CNS development. Work in model systems has demonstrated rescue of pathophysiological and behavioral abnormalities when IGF-1 is administered, and several clinical studies have shown promise of efficacy in disorders of the CNS, including autism spectrum disorder (ASD). In this review, we explore the molecular pathways and downstream effects of IGF-1 and summarize the results of completed and ongoing pre-clinical and clinical trials using IGF-1 as a pharmacologic intervention in various CNS disorders. This aim of this review is to provide evidence for the potential of IGF-1 as a treatment for neurodevelopmental disorders and ASD.</p>
</abstract>
<kwd-group>
<kwd>IGF-1</kwd>
<kwd>insulin-like growth factor 1</kwd>
<kwd>neurotrophic factors</kwd>
<kwd>central nervous system disorders</kwd>
<kwd>CNS development</kwd>
<kwd>neurodevelopmental disorders</kwd>
<kwd>ASD</kwd>
<kwd>autism spectrum disorder</kwd>
<kwd>Fragile X syndrome</kwd>
<kwd>Phelan-McDermid syndrome</kwd>
<kwd>Rett Syndrome</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>